Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement

European Respiratory Journal

Volumn 33, Issue 4, 2009, Pages 882-896

  Antoniou, K M ^a   Margaritopoulos, G ^a   Economidou, F ^a   Siafakas, N M ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Bronchoalveolar lavage fluid; Collagen vascular diseases; Connective tissue disorders; Interstitial lung disease; Pulmonary fibrosis; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL MARKER; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSPNEA; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INCIDENCE; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MIXED CONNECTIVE TISSUE DISEASE; MORBIDITY; MORTALITY; NEUTROPENIA; NEUTROPHILIA; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION;

BIOLOGICAL MARKERS; BIOPSY; BRONCHOALVEOLAR LAVAGE; CONNECTIVE TISSUE DISEASES; DISEASE PROGRESSION; EXERCISE TEST; HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS;

EID: 63849343420     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00152607     Document Type: Review

References (183)

1. Crestani B. The respiratory system in connective tissue disorders. Allergy 2005; 60: 715-734.
2. American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
3. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006; 12: 346-353.
4. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691-697.
5. Horton MR. Rheumatoid arthritis associated interstitial lung disease. Crit Rev Comput Tomogr 2004; 45: 429-440.
6. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722-732.
7. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019-2027.
8. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 2005; 26: 121-125.
9. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996; 39:1711-1719.
10. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis- related lung diseases: CT findings. Radiology 2004; 232: 81-91.
11. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases in collagen vascular diseases. Eur Respir J 2001; 32: Suppl. 45, 69s-80s.
12. Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 10-17.
13. Brown KK. Rheumatoid Lung Disease. Proc Am Thorac Soc 2007; 4: 443-448.
14. Akira M, Sakatani M, Hara H. Thin-section CT findings in rheumatoid arthritis associated lung disease: CT patterns and their courses. J Comput Assist Tomogr 1999;23: 941-948.
15. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.
16. Fujita J, Ohtsuki Y, Yoshinouchi T, et al. Idiopathic nonspecific interstitial pneumonia: as an ''autoimmune interstitial pneumonia''. Respir Med 2005; 99: 234-240.
17. Sato T, Fujita J, Yamadori I, et al. Nonspecific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders. Rheumatol Int 2006; 26:551-555.
18. Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford) 2001; 40: 1022-1025.
19. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622-627.
20. Banks J, Banks C, Cheong B, et al. An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis. QJ Med 1992; 85: 795-806.
21. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 517-521.
22. Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984; 85: 69-74.
23. Orens JB, Kazerooni EA, Martinez FJ, et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest 1995; 108: 109-115.
24. Chetta A, Aiello M, Foresi A, et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 170-175.
25. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168: 1084-1090.
26. McDonagh J, Greaves M, Wright AR, Heycock C, Owen JP, Kelly C. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994; 33: 118-122.
27. Cortet B, Flipo RM, Remy-Jardin M, et al. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 815-819.
28. Provenzano G. Asymptomatic pulmonary involvement in RA. Thorax 2002; 57: 187-188.
29. Ayhan-Ardic FF, Oken O, Yorgancioglu ZR, Ustun N, Gokharman FD. Pulmonary involvement in lifelong nonsmoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 2006; 25: 213-218.
30. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005; 25: 429-435.
31. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol 2004; 14: 272-280.
32. Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis: prospective study in 75 patients. Joint Bone Spine 2005; 72:41-47.
33. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41: 262-267.
34. Garcia JG, Parhami N, Killam D, Garcia PL, Keogh BA. Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis. Am Rev Respir Dis 1986; 133: 450-454.
35. Gilligan DM, O'Connor CM, Ward K, Moloney D, Bresnihan B, FitzGerald MX. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax 1990; 45: 591-596.
36. Gauhar UA, Gaffo AL, Alarcón GS. Pulmonary manifestations of rheumatoid arthritis. Semin Respir Crit Care Med 2007; 28: 430-440.
37. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998; 19: 667-685.
38. Zisman DA, McCune WJ, Tino G, Lynch JP III. Druginduced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 243-252.
39. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987; 16: 186-195.
40. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987; 14: 1164-1171.
41. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate- associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-1837.
42. Padley SP, Adler B, Hansell DM, Muller NL. High- resolution computed tomography of drug induced lung disease. Clin Radiol 1992; 46: 232-236.
43. Hacking JC, Flower CD. Causes and investigation of increasing dyspnoea in rheumatoid arthritis. Ann Rheum Dis 1995; 54: 17-19.
44. Fuhrman C, Parrot A, Wislez M, et al. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 2001; 164: 1186-1191.
45. Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 434-439.
46. Elsasser S, Dalquen P, Soler M, Perruchoud AP. Methotrexate-induced pneumonitis: appearance four weeks after discontinuation of treatment. Am Rev Respir Dis 1989; 140: 1089-1092.
47. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110.
48. Moreland LW, Baumgartner SW, Schiff MH, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33:1789-1801.
49. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-516.
50. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007; 25:23-28.
51. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593.
52. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329: 1266.
53. Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16: 206-211.
54. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 2002; 17:270-273.
55. Puttick MP, Klinkhoff AV, Chalmers A, Ostrow DN. Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. J Rheumatol 1995; 22: 2163-2165.
56. Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 1422-1424.
57. Ferri G, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serological features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-153.
58. Scussel-Lonzetti L, Joyal F, Raynauld J-P, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis and survival. Medicine (Baltimore) 2002; 81: 154-167.
59. Simeon CP, Armadans L, Fonollosa V, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003; 42: 71-75.
60. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-413.
61. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-1590.
62. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
63. Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60: 281-283.
64. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 121-127.
65. Lomeo RM, Cornella RJ, Schabel SI, Silver RM. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med 1989; 87:525-527.
66. Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006; 130: 976-981.
67. Hosoya N, Mimura T, Enokawa Y, et al. A rare case of cardiac sarcoidosis in a patient with progressive systemic sclerosis, Sjögren's syndrome, and polymyositis. Intern Med 1995; 34: 1164-1167.
68. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-1236.
69. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516-522.
70. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: the value of exercise testing. Chest 2001; 120: 93-101.
71. Spruit MA, Thomeer MJ, Gosselink R, et al. Skelet al muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60: 32-38.
72. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
73. Kawut SM, O'Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 2005; 99: 1431-1439.
74. Devaraj A, Wells AU, Hansell DM. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med 2007; 28: 389-397.
75. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232: 560-567.
76. Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33: 1789-1801.
77. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470-476.
78. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154: 400-406.
79. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA Cyclophosphamide is associated with pulmonary function, survival benefit in patients with scleroderma and alveolitis, Arch Intern Med 2000; 132: 947-954.
80. White B. Evaluation and management of pulmonary fibrosis in scleroderma. Curr Rheumatol Rep 2002; 4: 108-112.
81. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: bronchoalveolar lavage findings in relation to computed tomographic appearances. Am J Respir Crit Care Med 1994; 150: 462-468.
82. Wells AU, Hansell DM, Haslam PL, et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am J Respir Crit Care Med 1998; 157: 1474-1482.
83. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56: 2005-2012.
84. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
85. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in sclero- derma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-98.
86. Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease inpatients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 162: 258-263.
87. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31: 1112-1120.
88. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97-99.
89. Tashkin DP, Clements PJ, Wright RS, et al. Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis: a longitudinal analysis. Chest 1994; 105: 489-495.
90. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that could precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-1619.
91. DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46:2983-2989.
92. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-1034.
93. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematous. Lupus 2004; 13: 366-371.
94. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29:298-304.
95. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29:731-736.
96. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylpredniso- lone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371-2378.
97. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclopho- sphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-3970.
98. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjogren's syndrome: a clinical, pathological, and serological study of sixty-two cases. Medicine 1965; 44: 187-231.
99. Moutsopoulos HM, Chused TM, Mann DL, et al. Sjogren's syndrome (Sicca syndrome): current issues. Ann Intern Med 1980; 92: 212-226.
100. Manthorpe R, Asmussen K, Oxholm PJ. Primary Sjogren's syndrome: diagnostic criteria, clinical features, and disease activity. Rheumatology 1997; 24: 8-11.
101. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjogren's syndrome: clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996; 154: 794-799.
102. Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjogren's syndrome. Clin Chest Med 1998; 19:687-699.
103. Davidson BKS, Kelly CA, Griffiths ID. Ten-year follow up of pulmonary function in patients with primary Sjogren's syndrome. Thorax 2000; 59: 709-712.
104. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171:632-638.
105. Honda O, Johkoh T, Ichikado K, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol. 1999; 173: 71-74.
106. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44: 585-596.
107. Yamadori I, Fujita J, Bandoh S, et al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjogren's syndrome. Rheumatol Int 2002; 22: 89-92.
108. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
109. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjogren syndrome. Chest 2006; 130: 1489-1495.
110. Matsuyama N, Ashizawa K, Okimoto T, Kadota J, Amano H, Hayashi K. Pulmonary lesions associated with Sjogren's syndrome: radiographic and CT findings. Br J Radiol 2003; 76: 880-884.
111. Hatron PY, Wallaert B, Gosset D, et al. Subclinical lung inflammation in primary Sjogren's syndrome. Relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease. Arthritis Rheum 1987; 30:1226-1231.
112. Wallaert B, Prin L, Hatron PY, Ramon P, Tonnel AB, Voisin C. Lymphocyte subpopulations in bronchoalveolar lavage in Sjogren's syndrome. Evidence for an expansion of cytotoxic/suppressor subset in patients with alveolar neutrophilia. Chest 1987; 92: 1025-1031.
113. Wallaert B, Hatron PY, Grosbois JM, Tonnel AB, Devulder B, Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronch-oalveolar lavage. Am Rev Respir Dis 1986; 133: 574-580.
114. Callen JP. Dermatomyositis. Lancet 2000; 355: 53-57.
115. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 2001; 28:2230-2237.
116. Marie I, Hatron PY, Hachulla E, Wallaert B, Michon- Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998;25: 1336-1343.
117. Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine 1999; 78: 139-147.
118. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermato-myositis. Ann Rheum Dis 2004; 63: 297-301.
119. Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614-622.
120. Hirakata M, Nakamura K, Kaburaki J, et al. : Interstitial lung disease in patients with connective tissue diseases.:: Nihon Kyobu Shikkan Gakkai Zasshi 1995;33: Suppl., 268-276.
121. Lakhanpal S, Lie JT, Conn DL, Martin WJ 2nd, Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1987; 46: 23-29.
122. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988; 18: 29-37.
123. Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987; 14: 102-107.
124. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 16: 1182-1185.
125. Grau JM, Miró O, Pedrol E, et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 1996;23: 1921-1926.
126. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2000;12: 501-508.
127. Marie I, Dominique S, Rémy-Jardin M, Hatron PY, Hachulla E. Interstitial lung diseases in polymyositis and dermatomyositis. Rev Med Interne 2001; 22:1083-1096.
128. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermato- myositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32: 273-284.
129. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermato- myositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141: 727-733.
130. Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007; 101: 1761-1769.
131. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347.
132. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407.
133. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Chronological evaluation of the onset of histologically confirmed interstitial pneumonia associated with poly- myositis/dermatomyositis. Intern Med 2002; 41:1135-1141.
134. razer RS, Muller NL, Colman N, et al. International pneumonitis in association with polymyositis and derma- tomyositis. In: Fraser R, Muller N, Colman N, Pare P, eds. Diagnosis Of Diseases Of The Chest. London, Saunders,1999; pp. 1462-1465.
135. Marvin I, Schwarz MD. Pulmonary and cardiac manifestations of polymyositis-dermatomyosytis. J Thor Imaging 1992; 7: 46-54.
136. Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol 2004; 49:235-244.
137. Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003; 123: 1096-1103.
138. Akira M, Hara H, Sakatani M. Interstitial lung disease in association with polymyositis-dermatomyositis: long- term follow-up CT evaluation in seven patients. Radiology 1999; 210: 333-338.
139. Mino M, Noma S, Taguchi Y, Tomii K, Wu CL, Chen PJ. Pulmonary involvement in polymyositis and dermato- myositis: sequential evaluation with CT. AJR Am J Roentgenol 1997; 169: 83-87.
140. Ito M, Kaise S, Suzuki S, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245-250.
141. Lee CS, Chen TL, Tzen CY, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 2002; 21: 391-396.
142. Kazenstein AA, Fiorelli RF. Non specific interstitial pneumonia/fibrosis: Histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136-147.
143. Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005; 44: 1282-1286.
144. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245-250.
145. Evans J. Antinuclear antibody testing in systemic autoimmune disease. Clin Chest Med 1998; 19: 613-625.
146. Ihn H, Asano Y, Kubo M, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology 2002; 41: 1268-1272.
147. Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 2000; 59: 257-262.
148. Deng J, Keane MP, Lynch III JP. Pulmonary complications of polymyositis and dermatomyositis. In: Wells AU, Denton CP, eds. Pulmonary Involvement in Systemic Autoimmune Diseases. London, Elsevier, 2004; pp. 209-226.
149. Cherin P, Pelletier S, Teixeira A, et al. Results and long- term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46:467-474.
150. King TE Jr, Cherniack RM, Schwarz MI. The lungs and connective tissue diseases. In: Murray JF, Nadel JA, eds. Textbook Of Respiratory Medicine. Philadelphia: WB Saunders, 1994; pp. 1850-1872.
151. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77:195-207.
152. Hochberg MC. Updating American College of Rheumatology revised criteria for the classification of systemic lupus erythematosous. Arhritis Rheum 1997; 40: 1725.
153. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5- year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78: 167-175.
154. Murin S, Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 1998; 19: 641-665.
155. Fenlon HM, Doran M, Sant SM, Breatnach E. High resolution CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996; 166: 301-307.
156. Bankier AA, Kiener HP, Wiesmayr MN, et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology 1995; 196: 835-840.
157. Sant SM, Doran M, Fenelon HM, Breatnach ES. Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests. Clin Exp Rheumatol 1997; 15: 507-513.
158. Filipek MS, Thompson ME, Wang PL, Gosselin MV, L Primack S. Lymphocytic interstitial pneumonitis in a patient with systemic lupus erythematosus: radiographic and high-resolution CT findings. J Thorac Imaging 2004; 19: 200-203.
159. Yood RA, Steigman DM, Gill LR. Lymphocytic interstitial pneumonitis in a patient with systemic lupus erythematosus. Lupus 1995; 4: 161-163.
160. Yum HK, Kim ES, Ok KS, Lee HK, Choi SJ. Lymphocytic interstitial pneumonitis associated with Epstein-Barr virus in systemic lupus erythematosus and Sjogren's Syndrome. Complete remission with corticosteriod and cyclophosphamide. Korean J Intern Med 2002; 17: 198-203.
161. Min JK, Hong YS, Park SH, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 2254-2257.
162. Otsuka F, Amano T, Hashimoto N, et al. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus with antiphospholipid antibody. Intern Med 1996; 35: 341-344.
163. Gammon RB, Bridges TA, al-Nezir H, Alexander CB, Kennedy JI Jr. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus. Chest 1992; 102: 1171-1174.
164. Paran D, Koifman B, Elkayam O, et al. Echocardiography, pulmonary function testing and induced sputum evaluation in systemic lupus erythematosous and the antipho-spholipid syndrome. Lupus 2002; 11: 546.
165. Myers JL, Katzenstein AA. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol 1986;85: 552-556.
166. Eisenberg H, Dubois EL, Sherwin RP, Balchum OJ. Diffuse interstitial lung disease in systemic lupus erythematosus. Ann Intern Med 1973; 79: 37-45.
167. Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20: 48-56.
168. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol 1989; 16: 479-481.
169. Groen H, ter Borg EJ, Postma DS, Wouda AA, van der Mark TW, Kallenberg CG. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med 1992; 93: 619-627.
170. Leatherman JW, Davies SF, Hoidal JR. Alveolar hemorrhage syndromes: diffuse microvascular lung hemorrhage in immune and idiopathic disorders. Medicine (Baltimore) 1984; 63: 343-361.
171. Schwab EP, Schumacher HR Jr, Freundlich B, Callegari PE. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 1993; 23: 8-15.
172. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148-159.
173. Kasukawa R, Sharp GC. Mixed Connective Tissue Diseases and Antinuclear Antibodies. Amsterdam, Elsevier, 1987.
174. Venables PJ. Mixed connective tissue disease. Lupus 2006;15: 132-137.
175. Prakash UB. Respiratory complications in mixed connective tissue disease. Clin Chest Med 1998; 19: 733-746.
176. Kozuka T, Johkoh T, Honda O, et al. Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging 2001; 16: 94-98.
177. Tojo T, Ogasawara T, Aotsuka S, Yokohari R. Major Causes of Death and Five Year Survival Rates in Mixed Connective Tissue Disease. 1990 Annual Report of the Research Committee of Japanese Ministry of Health and Welfare for Mixed Connective Tissue Disease. Japanese Ministry of Health and Welfare, 1991; pp. 10-13.
178. Ichikawa Y, Tsunematsu T, Yokohari R, et al. Multicenter study of causes of death in systemic lupus erythematosous - a report from Subcommittee for Development of Therapy, the Research Committee for Autoimmune Diseases Supported by Ministry of Health and Welfare. Ryumachi 1985; 25: 258-264.
179. Kaburaki J, Lee CC, Ogasawara T, Okano H, Tojo T. Clinical study of progressive systemic sclerosis (PSS) patients with poor prognosis. Annual Report of the Ministry of Health and Welfare Scleroderma Research Committee 1998. Japanese Ministry of Health and Welfare, 1998; pp. 314-318.
180. Esther JH, Sharp GH, Agia G, Hurst DJ, Maricq HR. Pulmonary hypertension in a patient with connective tissue disease and antibody to nuclear ribonucleoprotein. Arthritis Rheum 1981; 24: 2105.
181. Miyawaki S, Onodera H, Kasukawa R, Nishimaki T. Multicenter study on therapy and prognosis of mixed connective tissue disease. In: Kasukawa R, ed. Proceedings of the Symposium on Therapy, Disease Type and Pulmonary Hypertension of Mixed Connective Tissue Disease. Research Committee of the Japanese Ministry of Health and Welfare for Mixed Connective Tissue Disease, 1991; pp. 26-35.
182. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003; 15: 748-755.
183. Antoniou KM, Wells AU. Scerloderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 2008; 20: 686-691.